Investment Thesis
Inhibrx exhibits severe financial distress with negative stockholders' equity of -$21M, mounting operating losses (-$30.9M) that are worsening relative to minimal revenue ($1.3M), and negative free cash flow of -$38M annually. While the company possesses adequate cash runway (~4 years), the fundamentals reveal unsustainable unit economics and deteriorating financial health that requires near-term profitability or capital restructuring.
Strengths
- Strong liquidity position with $161.7M cash providing 4+ years of operational runway
- Exceptional revenue growth rate of 550% YoY indicating early commercial traction despite minimal absolute revenue
- Capital-efficient operations with zero capital expenditures, suggesting focused R&D spending
Risks
- Negative stockholders' equity of -$21M indicates technical insolvency and balance sheet deterioration
- Net losses worsening YoY (-108.3% decline) with operating margin of -2379%, demonstrating accelerating cash burn unsustainable without profitability
- Liabilities exceed total assets by $21M with $175M long-term debt burden; high leverage with negative interest coverage and no clear path to debt servicing from operations
Key Metrics to Watch
- Operating cash flow trajectory and monthly cash burn rate to assess runway duration
- Revenue growth sustainability and path to gross profitability given current 550% growth rate
- Stockholders' equity recovery timeline and whether debt restructuring or capital raise is required
Financial Metrics
Revenue
1.3M
Net Income
-33.4M
EPS (Diluted)
$-2.15
Free Cash Flow
-38.0M
Total Assets
184.0M
Cash
161.7M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-2,379.0%
Net Margin
-2,572.4%
ROE
N/A
ROA
-18.2%
FCF Margin
-2,925.1%
Balance Sheet & Liquidity
Current Ratio
6.46x
Quick Ratio
6.46x
Debt/Equity
N/A
Debt/Assets
111.4%
Interest Coverage
N/A
Long-term Debt
175.0M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-15T09:32:12.855484 |
Data as of: 2026-03-31 |
Powered by Claude AI